AbbVie beat earnings expectations and raised its outlook as newer drugs offset Humira's decline

Skyrizi and Rinvoq together generated more than $6.6 billion in quarterly sales, far outpacing Humira's $688 million

NurPhoto / Getty Images

AbbVie raised its full-year adjusted earnings forecast after first-quarter results exceeded expectations, driven by strong demand for its newer immunology drugs Skyrizi and Rinvoq as sales of former top seller Humira continued to fall.

Raising its outlook, the company set a new full-year adjusted diluted earnings target of $14.08 to $14.28 per share, compared with its previous guidance of $13.96 to $14.16. First-quarter adjusted diluted earnings........

© Quartz